REPROFILING of drugs designed for one indication for a new condition is not new, but it is a great strategy, as toxicology is de-risked, as the drug has typically already been in man, and enjoys a shorted approval. While popular among small specialty Pharma companies, big Pharma has tended to ignore it due to the lack of Composition of Matter IP, and a supposedly weaker Use patent protection. There have been recent European initiatives to comb through these abandoned molecules systematically, which is a sea-change of historically limited access by big Pharma to these shelved projects. ”
”
http://lnkd.in/En83UE
linkedin post 2022-06-29 05:12:48
Nigel Fleming
September 21, 2022